BioprintingCompany Visits

CELLINK showcases bioprinting progress at the Collaborative Partnership Conference

Bioprinting company CELLINK is continually striving to advance the possibilities of additive manufacturing in the medical, and specifically bioprinting, field. To highlight its efforts, the company recently hosted a Collaborative Partnership Conference on May 10 in Milan, Italy. The event was the perfect opportunity to showcase the technological solutions offered by the company and, above all, the current use cases for them.

The event was held at the San Raffaele Hospital and brought together various Italian and foreign companies that are using CELLINK’s bioprinters to develop highly innovative research projects. Arguably the most relevant were the case studies shown by the San Raffaele Scientific Institute and by the University of Pavia, the most 3D printing-oriented university in Italy known for opening 3D4Med, the first Clinical 3D Printing Laboratory in Italy and one of the few international companies of its kind.

Collaborative Partnership Conference
The Lumen X 3D bioprinter leverages biocompatible blue light for high resolution tissue printing.

The CELLINK Collaborative Partnership Conference provided a comprehensive overview of the applicability of bioprinting in critical fields such as research for autoimmune diseases treatments and regenerative medicine, with a lot of examples that demonstrate how CELLINK’s systems can help experts to obtain concrete results and more reliability. Most importantly, this general overview of concrete use cases proves that the company’s 3D bioprinting is an important tool for medical and scientific research.

In the end, the Collaborative Partnership Conference was an opportunity to see the Lumen X bioprinter in action. The machine, released in March 2019, was developed for the vascular sector in partnership with Volumetric. Thanks to one million light points, it is capable of bioprinting microscopic features down to 200 microns. With this capability, the Lumen X could mark a real turning point for vascular research, assuring the fast production of complex vascular structures.

[Originally published on Replicatore]

Tags

Matteo Maggioni

Matteo brings extensive experience as a professional tech journalist to 3DPBM’s Italian editorial website, Replicatore. He has been involved since the very beginning, and has continued to cover the AM industry and its many evolutions. He keeps an eye on its potential to reach the consumer target. Matteo lives and works in Milan, Italy and received his degree from Università degli Studi di Milano, Italy.

Related Articles

Leave a Reply

Your email address will not be published.

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services
Close
Close

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!